Cargando…

Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry

Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs. Given their origin, they or their precursors must be circulating cells before recruitment into target tissues. While most...

Descripción completa

Detalles Bibliográficos
Autores principales: Reese, Charles, Lee, Rebecca, Bonner, Michael, Perry, Beth, Heywood, Jonathan, Silver, Richard M., Tourkina, Elena, Visconti, Richard P., Hoffman, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058709/
https://www.ncbi.nlm.nih.gov/pubmed/24999331
http://dx.doi.org/10.3389/fphar.2014.00141
_version_ 1782321163276386304
author Reese, Charles
Lee, Rebecca
Bonner, Michael
Perry, Beth
Heywood, Jonathan
Silver, Richard M.
Tourkina, Elena
Visconti, Richard P.
Hoffman, Stanley
author_facet Reese, Charles
Lee, Rebecca
Bonner, Michael
Perry, Beth
Heywood, Jonathan
Silver, Richard M.
Tourkina, Elena
Visconti, Richard P.
Hoffman, Stanley
author_sort Reese, Charles
collection PubMed
description Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs. Given their origin, they or their precursors must be circulating cells before recruitment into target tissues. While most previous studies focused on circulating fibrocytes, here we focus on the fibrocyte phenotype in fibrotic tissue. The study's relevance to human disease is heightened by use of a model in which bleomycin is delivered systemically, recapitulating several features of human scleroderma including multi-organ fibrosis not observed when bleomycin is delivered directly into the lungs. Using flow cytometry, we find in the fibrotic lung a large population of CD45(high) fibrocytes (called Region I) rarely found in vehicle-treated control mice. A second population of CD45+ fibrocytes (called Region II) is observed in both control and fibrotic lung. The level of CD45 in circulating fibrocytes is far lower than in either Region I or II lung fibrocytes. The chemokine receptors CXCR4 and CCR5 are expressed at higher levels in Region I than in Region II and are present at very low levels in all other lung cells including CD45+/collagen I- leucocytes. The collagen chaperone HSP47 is present at similar high levels in both Regions I and II, but at a higher level in fibrotic lung than in control lung. There is also a major population of HSP47(high)/CD45- cells in fibrotic lung not present in control lung. CD44 is present at higher levels in Region I than in Region II and at much lower levels in all other cells including CD45+/collagen I- leucocytes. When lung fibrosis is inhibited by restoring caveolin-1 activity using a caveolin-1 scaffolding domain peptide (CSD), a strong correlation is observed between fibrocyte number and fibrosis score. In summary, the distinctive phenotype of fibrotic lung fibrocytes suggests that fibrocyte differentiation occurs primarily within the target organ.
format Online
Article
Text
id pubmed-4058709
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40587092014-07-04 Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry Reese, Charles Lee, Rebecca Bonner, Michael Perry, Beth Heywood, Jonathan Silver, Richard M. Tourkina, Elena Visconti, Richard P. Hoffman, Stanley Front Pharmacol Pharmacology Fibrocytes are bone marrow hematopoietic-derived cells that also express a mesenchymal cell marker (commonly collagen I) and participate in fibrotic diseases of multiple organs. Given their origin, they or their precursors must be circulating cells before recruitment into target tissues. While most previous studies focused on circulating fibrocytes, here we focus on the fibrocyte phenotype in fibrotic tissue. The study's relevance to human disease is heightened by use of a model in which bleomycin is delivered systemically, recapitulating several features of human scleroderma including multi-organ fibrosis not observed when bleomycin is delivered directly into the lungs. Using flow cytometry, we find in the fibrotic lung a large population of CD45(high) fibrocytes (called Region I) rarely found in vehicle-treated control mice. A second population of CD45+ fibrocytes (called Region II) is observed in both control and fibrotic lung. The level of CD45 in circulating fibrocytes is far lower than in either Region I or II lung fibrocytes. The chemokine receptors CXCR4 and CCR5 are expressed at higher levels in Region I than in Region II and are present at very low levels in all other lung cells including CD45+/collagen I- leucocytes. The collagen chaperone HSP47 is present at similar high levels in both Regions I and II, but at a higher level in fibrotic lung than in control lung. There is also a major population of HSP47(high)/CD45- cells in fibrotic lung not present in control lung. CD44 is present at higher levels in Region I than in Region II and at much lower levels in all other cells including CD45+/collagen I- leucocytes. When lung fibrosis is inhibited by restoring caveolin-1 activity using a caveolin-1 scaffolding domain peptide (CSD), a strong correlation is observed between fibrocyte number and fibrosis score. In summary, the distinctive phenotype of fibrotic lung fibrocytes suggests that fibrocyte differentiation occurs primarily within the target organ. Frontiers Media S.A. 2014-06-16 /pmc/articles/PMC4058709/ /pubmed/24999331 http://dx.doi.org/10.3389/fphar.2014.00141 Text en Copyright © 2014 Reese, Lee, Bonner, Perry, Heywood, Silver, Tourkina, Visconti and Hoffman. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Reese, Charles
Lee, Rebecca
Bonner, Michael
Perry, Beth
Heywood, Jonathan
Silver, Richard M.
Tourkina, Elena
Visconti, Richard P.
Hoffman, Stanley
Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
title Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
title_full Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
title_fullStr Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
title_full_unstemmed Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
title_short Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
title_sort fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058709/
https://www.ncbi.nlm.nih.gov/pubmed/24999331
http://dx.doi.org/10.3389/fphar.2014.00141
work_keys_str_mv AT reesecharles fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT leerebecca fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT bonnermichael fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT perrybeth fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT heywoodjonathan fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT silverrichardm fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT tourkinaelena fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT viscontirichardp fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry
AT hoffmanstanley fibrocytesinthefibroticlungalteredphenotypedetectedbyflowcytometry